5-HT3 길항제 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "5-HT3 길항제" in Korean language version.

refsWebsite

Global rank Korean rank

20nih.gov

4^th place

18doi.org

2^nd place

3^rd place

4semanticscholar.org

11^th place

310^th place

4web.archive.org

1^st place

3archive.org

6^th place

18^th place

2medscape.com

719^th place

424^th place

1who.int

195^th place

98^th place

1allacademic.com

low place

1mfds.go.kr

low place

1,240^th place

1health.kr

low place

2,285^th place

1alphamedpress.org

low place

1docguide.com

low place

1mims-online.com

low place

1fda.gov

447^th place

433^rd place

1pharmatimes.com

low place

1drugs.com

399^th place

141^st place

1springer.com

274^th place

294^th place

1uchsc.edu

low place

1wiley.com

222^nd place

164^th place

1archive.today

14^th place

15^th place

1psychiatryonline.org

4,032^nd place

8,074^th place

1oregonstate.edu

2,041^st place

1,281^st place

allacademic.com

Dula D, Rosenbach S (2006). "A randomized clinical trial comparing ondansetron with placebo in aeromedical personel with motion sickness". Paper presented at the annual meeting of the National Association of EMS Physicians, Registry Resort, Naples, FL, January 19–21, 2006. Retrieved on April 25, 2009.

alphamedpress.org

theoncologist.alphamedpress.org

Aapro M (2004). “Granisetron: an update on its clinical use in the management of nausea and vomiting”. 《Oncologist》 9 (6): 673–86. doi:10.1634/theoncologist.9-6-673. PMID 15561811. Free full text Archived 2009년 8월 10일 - 웨이백 머신

archive.org

Stott JR, Barnes GR, Wright RJ, Ruddock CJ (1989). “The effect on motion sickness and oculomotor function of GR 38032F, a 5-HT3-receptor antagonist with anti-emetic properties”. 《British Journal of Clinical Pharmacology》 27 (2): 147–57. doi:10.1111/j.1365-2125.1989.tb05345.x. PMC 1379774. PMID 2523720.
Costall B, Gunning SJ, Naylor RJ, Tyers MB (1987). “The effect of GR38032F, novel 5-HT3-receptor antagonist on gastric emptying in the guinea-pig”. 《Br. J. Pharmacol.》 91 (2): 263–4. doi:10.1111/j.1476-5381.1987.tb10280.x. PMC 1853517. PMID 2955843.
Brunton, Laurence L.; Lazo, John S.; Parker, Keith L. (2006). 《Goddman & Gilman's The Pharmacological Basis of Therapeutics》. New York: McGraw-Hill. 1000–3쪽. ISBN 978-0-07-142280-2.

archive.today

Kim S; Shin, IS; Kim, JM; Kang, HC; Mun, JU; Yang, SJ; Yoon, JS (2006). “Mirtazapine for Severe Gastroparesis Unresponsive to Conventional Prokinetic Treatment”. 《Psychosomatics》 47 (5): 440–442. doi:10.1176/appi.psy.47.5.440. PMID 16959934. 2012년 7월 14일에 원본 문서에서 보존된 문서. 2009년 3월 4일에 확인함.

docguide.com

“FDA Approves Aloxi (Palonosetron) For Treatment of Chemotherapy-Related Nausea and Vomiting” (보도 자료). Doctor's Guide Publishing Limited. 2003년 7월 28일. 2007년 5월 15일에 확인함.

doi.org

dx.doi.org

de Wit R, Aapro M, Blower PR (2005). “Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?”. 《Cancer Chemother Pharmacol》 56 (3): 231–8. doi:10.1007/s00280-005-1033-0. PMID 15838653. S2CID 27576150.
Herrstedt, J.; Aapro, M. S.; Roila, F.; Kataja, V. V.; ESMO Guidelines Task Force (2005). “"ESMO Minimum Clinical Recommendations for prophylaxis of chey-induced nausea and vomiting (NV)".”. 《Annals of Oncology》 16: i77–i79. doi:10.1093/annonc/mdi805. PMID 15888767.
Lindley C, Blower P (2000). “Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis”. 《Am J Health-Syst Pharm》 57 (18): 1685–97. doi:10.1093/ajhp/57.18.1685. PMID 11006796. Free full text with registration at Medscape
Roila F, Fatigoni S (2006). “New antiemetic drugs”. 《Ann Oncol》. 17 Suppl 2: ii96–100. doi:10.1093/annonc/mdj936. PMID 16608997.
Stott JR, Barnes GR, Wright RJ, Ruddock CJ (1989). “The effect on motion sickness and oculomotor function of GR 38032F, a 5-HT3-receptor antagonist with anti-emetic properties”. 《British Journal of Clinical Pharmacology》 27 (2): 147–57. doi:10.1111/j.1365-2125.1989.tb05345.x. PMC 1379774. PMID 2523720.
Hagan RM, Butler A, Hill JM, Jordan CC, Ireland SJ, Tyers MB (1987). “Effect of the 5-HT3 receptor antagonist, GR38032F, on responses to injection of a neurokinin agonist into the ventral tegmental area of the rat brain”. 《Eur. J. Pharmacol.》 138 (2): 303–5. doi:10.1016/0014-2999(87)90450-X. PMID 2442006.
Costall B, Gunning SJ, Naylor RJ, Tyers MB (1987). “The effect of GR38032F, novel 5-HT3-receptor antagonist on gastric emptying in the guinea-pig”. 《Br. J. Pharmacol.》 91 (2): 263–4. doi:10.1111/j.1476-5381.1987.tb10280.x. PMC 1853517. PMID 2955843.
Aapro M (2004). “Granisetron: an update on its clinical use in the management of nausea and vomiting”. 《Oncologist》 9 (6): 673–86. doi:10.1634/theoncologist.9-6-673. PMID 15561811. Free full text Archived 2009년 8월 10일 - 웨이백 머신
Sorensen SM, Humphreys TM, Palfreyman MG (1989). “Effect of acute and chronic MDL 73,147EF, a 5-HT3 receptor antagonist, on A9 and A10 dopamine neurons”. 《Eur. J. Pharmacol.》 163 (1): 115–8. doi:10.1016/0014-2999(89)90402-0. PMID 2744086.
De Leon A (2006). “Palonosetron (Aloxi): a second-generation 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting”. 《Proceedings (Baylor University. Medical Center)》 19 (4): 413–6. doi:10.1080/08998280.2006.11928210. PMC 1618755. PMID 17106506.
Rabasseda X (February 2002). “Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting”. 《Drugs of Today》 38 (2): 75–89. doi:10.1358/dot.2002.38.2.820104. PMID 12532186.
Hirata T, Funatsu T, Keto Y, Nakata M, Sasamata M (February 2007). “Pharmacological profile of ramosetron, a novel therapeutic agent for IBS”. 《Inflammopharmacology》 15 (1): 5–9. doi:10.1007/s10787-006-1537-1. PMID 17323187. S2CID 29179265.
Huang QR; Iwamoto M; Aoki S; 외. (1991). “Anti-5-hydroxytryptamine3 effect of galanolactone, diterpenoid isolated from ginger”. 《Chem Pharm Bull》 39 (2): 397–9. doi:10.1248/cpb.39.397. PMID 2054863.
Kast R E; Foley, KF (2007). “Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects”. 《European Journal of Cancer Care》 16 (4): 351–354. doi:10.1111/j.1365-2354.2006.00760.x. PMID 17587360. ^{[깨진 링크]}
Kim S; Shin, IS; Kim, JM; Kang, HC; Mun, JU; Yang, SJ; Yoon, JS (2006). “Mirtazapine for Severe Gastroparesis Unresponsive to Conventional Prokinetic Treatment”. 《Psychosomatics》 47 (5): 440–442. doi:10.1176/appi.psy.47.5.440. PMID 16959934. 2012년 7월 14일에 원본 문서에서 보존된 문서. 2009년 3월 4일에 확인함.
Gan TJ (2005). “Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?”. 《CNS Drugs》 19 (3): 225–38. doi:10.2165/00023210-200519030-00004. PMID 15740177. S2CID 23209789.
Sanger GJ (September 2008). “5-hydroxytryptamine and the gastrointestinal tract: where next?”. 《Trends in Pharmacological Sciences》 29 (9): 465–71. doi:10.1016/j.tips.2008.06.008. PMID 19086255.
Aapro M (2005). “5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment”. 《Oncology》 69 (2): 97–109. doi:10.1159/000087979. PMID 16131816. S2CID 71759860.

drugs.com

“Calmactin Approval Status”. Drugs.com. 2019년 8월 14일에 확인함.

fda.gov

accessdata.fda.gov

GlaxoSmithKline (2005). “Lotronex Prescribing Information” (PDF). (203 KiB). U.S. Food and Drug Administration. Retrieved on 2009-07-30.

health.kr

“카비그라니세트론주(3mL)”. 《약학정보원》. 2023년 4월 7일에 확인함.

medscape.com

Lindley C, Blower P (2000). “Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis”. 《Am J Health-Syst Pharm》 57 (18): 1685–97. doi:10.1093/ajhp/57.18.1685. PMID 11006796. Free full text with registration at Medscape
Waknine, Yael (2008년 9월 4일). “FDA Approvals: Nplate, Aloxi, Vidaza”. Medscape. 2008년 12월 2일에 원본 문서에서 보존된 문서. 2008년 9월 4일에 확인함. Freely available with registration.

mfds.go.kr

nedrug.mfds.go.kr

“나보반주사(트로피세트론염산염)”. 《식품의약품안전처 의약품통합정보시스템》. 2023년 4월 7일에 확인함.

mims-online.com

Abridged prescribing information - Nasea (MIMS Philippines)^{[깨진 링크(과거 내용 찾기)]}. Retrieved on June 13, 2008.

nih.gov

ncbi.nlm.nih.gov

de Wit R, Aapro M, Blower PR (2005). “Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?”. 《Cancer Chemother Pharmacol》 56 (3): 231–8. doi:10.1007/s00280-005-1033-0. PMID 15838653. S2CID 27576150.
Herrstedt, J.; Aapro, M. S.; Roila, F.; Kataja, V. V.; ESMO Guidelines Task Force (2005). “"ESMO Minimum Clinical Recommendations for prophylaxis of chey-induced nausea and vomiting (NV)".”. 《Annals of Oncology》 16: i77–i79. doi:10.1093/annonc/mdi805. PMID 15888767.
Lindley C, Blower P (2000). “Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis”. 《Am J Health-Syst Pharm》 57 (18): 1685–97. doi:10.1093/ajhp/57.18.1685. PMID 11006796. Free full text with registration at Medscape
Roila F, Fatigoni S (2006). “New antiemetic drugs”. 《Ann Oncol》. 17 Suppl 2: ii96–100. doi:10.1093/annonc/mdj936. PMID 16608997.
Stott JR, Barnes GR, Wright RJ, Ruddock CJ (1989). “The effect on motion sickness and oculomotor function of GR 38032F, a 5-HT3-receptor antagonist with anti-emetic properties”. 《British Journal of Clinical Pharmacology》 27 (2): 147–57. doi:10.1111/j.1365-2125.1989.tb05345.x. PMC 1379774. PMID 2523720.
Levine ME, Chillas JC, Stern RM, Knox GW (2000). “The effects of serotonin (5-HT3) receptor antagonists on gastric tachyarrhythmia and the symptoms of motion sickness”. 《Aviat Space Environ Med》 71 (11): 1111–4. PMID 11086664.
Muth ER, Elkins AN (July 2007). “High dose ondansetron for reducing motion sickness in highly susceptible subjects”. 《Aviat Space Environ Med》 78 (7): 686–92. PMID 17679566.
Hagan RM, Butler A, Hill JM, Jordan CC, Ireland SJ, Tyers MB (1987). “Effect of the 5-HT3 receptor antagonist, GR38032F, on responses to injection of a neurokinin agonist into the ventral tegmental area of the rat brain”. 《Eur. J. Pharmacol.》 138 (2): 303–5. doi:10.1016/0014-2999(87)90450-X. PMID 2442006.
Costall B, Gunning SJ, Naylor RJ, Tyers MB (1987). “The effect of GR38032F, novel 5-HT3-receptor antagonist on gastric emptying in the guinea-pig”. 《Br. J. Pharmacol.》 91 (2): 263–4. doi:10.1111/j.1476-5381.1987.tb10280.x. PMC 1853517. PMID 2955843.
Aapro M (2004). “Granisetron: an update on its clinical use in the management of nausea and vomiting”. 《Oncologist》 9 (6): 673–86. doi:10.1634/theoncologist.9-6-673. PMID 15561811. Free full text Archived 2009년 8월 10일 - 웨이백 머신
Sorensen SM, Humphreys TM, Palfreyman MG (1989). “Effect of acute and chronic MDL 73,147EF, a 5-HT3 receptor antagonist, on A9 and A10 dopamine neurons”. 《Eur. J. Pharmacol.》 163 (1): 115–8. doi:10.1016/0014-2999(89)90402-0. PMID 2744086.
De Leon A (2006). “Palonosetron (Aloxi): a second-generation 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting”. 《Proceedings (Baylor University. Medical Center)》 19 (4): 413–6. doi:10.1080/08998280.2006.11928210. PMC 1618755. PMID 17106506.
Rabasseda X (February 2002). “Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting”. 《Drugs of Today》 38 (2): 75–89. doi:10.1358/dot.2002.38.2.820104. PMID 12532186.
Hirata T, Funatsu T, Keto Y, Nakata M, Sasamata M (February 2007). “Pharmacological profile of ramosetron, a novel therapeutic agent for IBS”. 《Inflammopharmacology》 15 (1): 5–9. doi:10.1007/s10787-006-1537-1. PMID 17323187. S2CID 29179265.
Huang QR; Iwamoto M; Aoki S; 외. (1991). “Anti-5-hydroxytryptamine3 effect of galanolactone, diterpenoid isolated from ginger”. 《Chem Pharm Bull》 39 (2): 397–9. doi:10.1248/cpb.39.397. PMID 2054863.
Kast R E; Foley, KF (2007). “Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects”. 《European Journal of Cancer Care》 16 (4): 351–354. doi:10.1111/j.1365-2354.2006.00760.x. PMID 17587360. ^{[깨진 링크]}
Kim S; Shin, IS; Kim, JM; Kang, HC; Mun, JU; Yang, SJ; Yoon, JS (2006). “Mirtazapine for Severe Gastroparesis Unresponsive to Conventional Prokinetic Treatment”. 《Psychosomatics》 47 (5): 440–442. doi:10.1176/appi.psy.47.5.440. PMID 16959934. 2012년 7월 14일에 원본 문서에서 보존된 문서. 2009년 3월 4일에 확인함.
Gan TJ (2005). “Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?”. 《CNS Drugs》 19 (3): 225–38. doi:10.2165/00023210-200519030-00004. PMID 15740177. S2CID 23209789.
Sanger GJ (September 2008). “5-hydroxytryptamine and the gastrointestinal tract: where next?”. 《Trends in Pharmacological Sciences》 29 (9): 465–71. doi:10.1016/j.tips.2008.06.008. PMID 19086255.
Aapro M (2005). “5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment”. 《Oncology》 69 (2): 97–109. doi:10.1159/000087979. PMID 16131816. S2CID 71759860.

oregonstate.edu

pharmacy.oregonstate.edu

“5-Hydroxytryptamine3 (5-HT₃) Receptor Antagonists” (PDF). Oregon State University College of Pharmacy. 2003. 2013년 3월 13일에 원본 문서 (PDF)에서 보존된 문서. 2007년 5월 15일에 확인함.

pharmatimes.com

“Solvay's cilansetron "not approvable"”. PharmaTimes. 2005년 4월 4일. 2019년 8월 14일에 확인함.

psychiatryonline.org

psy.psychiatryonline.org

Kim S; Shin, IS; Kim, JM; Kang, HC; Mun, JU; Yang, SJ; Yoon, JS (2006). “Mirtazapine for Severe Gastroparesis Unresponsive to Conventional Prokinetic Treatment”. 《Psychosomatics》 47 (5): 440–442. doi:10.1176/appi.psy.47.5.440. PMID 16959934. 2012년 7월 14일에 원본 문서에서 보존된 문서. 2009년 3월 4일에 확인함.

semanticscholar.org

api.semanticscholar.org

de Wit R, Aapro M, Blower PR (2005). “Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?”. 《Cancer Chemother Pharmacol》 56 (3): 231–8. doi:10.1007/s00280-005-1033-0. PMID 15838653. S2CID 27576150.
Hirata T, Funatsu T, Keto Y, Nakata M, Sasamata M (February 2007). “Pharmacological profile of ramosetron, a novel therapeutic agent for IBS”. 《Inflammopharmacology》 15 (1): 5–9. doi:10.1007/s10787-006-1537-1. PMID 17323187. S2CID 29179265.
Gan TJ (2005). “Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?”. 《CNS Drugs》 19 (3): 225–38. doi:10.2165/00023210-200519030-00004. PMID 15740177. S2CID 23209789.
Aapro M (2005). “5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment”. 《Oncology》 69 (2): 97–109. doi:10.1159/000087979. PMID 16131816. S2CID 71759860.